• Home
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Jacinta Flattery O’Brien PhD
    • Jennifer Enmon PhD JD
    • Grant Shoebridge PhD
    • Kadri Elcoat
    • Kate Legge
    • Lesley White
    • Alex May
    • Christopher Coates
    • Jessica Chadbourne PhD
    • Joanne Grant
    • Emily Bristow
    • Brittany Deleon
    • Ana Maria Chaves
    • Erni Othman
    • Amber Cross
  • News
    • Pearce IP Blog
    • BioBlast™
  • Blog
  • BioBlast™
  • Contact Us
How medicine repurposing could unravel the pharma industry in Australia

How medicine repurposing could unravel the pharma industry in Australia

by Naomi Pearce, Jennifer Enmon PhD, Alex May, Emily Bristow | Feb 15, 2021 | Blog, Blog Alex, Blog Emily, Blog Jennifer, Blog Naomi

As discussed in Part 1 of this blog series, TGA has invited submissions by 23 March 2021 on its consultation paper released last Thursday designed to facilitate indication “repurposing”.  In particular, TGA has sought submissions on the potential obstacles and...
Exclusive licensees: are you stuck in a “No Standing” zone?

Exclusive licensees: are you stuck in a “No Standing” zone?

by Jessica Chadbourne PhD, Alex May | Feb 11, 2021 | Blog, Blog Alex, Blog Jessica

Under Australian law, patent infringement proceedings may be started in the Australian Federal Court only by a patentee or an exclusive licensee.[1]  When it comes to determining the identity of the patentee or exclusive licensee, the Court will look to the...
Supply of essential oil for topical use infringes method of treatment patent claims

Supply of essential oil for topical use infringes method of treatment patent claims

by Alex May, Naomi Pearce | Dec 23, 2020 | Blog, Blog Alex, Blog Naomi

Supply of essential oil for topical use infringes method of treatment patent claims Justice Nicholas’ 96-page judgment in John Hood v Bush Pharmacy Pty Ltd [2020] FCA 1686 raises numerous legal issues including contributory infringement under s. 117 of the Patents Act...
Preliminary discovery not justified by fear of a future product launch

Preliminary discovery not justified by fear of a future product launch

by Alex May, Naomi Pearce | Dec 1, 2020 | Blog, Blog Alex, Blog Naomi

In Pfizer Ireland Pharmaceuticals v Sandoz Pty Ltd [2020] FCA 1648, the Federal Court of Australia declined to order preliminary discovery against Sandoz, the holder of an ARTG registration for biosimilar etanercept, that had no present intention to launch its ERELZI®...

SUBSCRIBE TO PEARCE IP

Sign up to our latest news

Receive our Pearce IP Blog and weekly BioBlast™ via email.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast™
  • Contact Us
  • Follow

Copyright © 2021 Pearce IP. All Rights Reserved.

Contact Us

Email: info@pearceIP.law
Tel: +61 (0) 2 9023 9988

For any general inquiries, please fill in the following contact form:

 





    Subscribe to our BioBlast™

    Fill in the form below to recieve our BioBlast™ Updates, Pearce IP Blog and other relevant industry updates.

     



      What emails do you want to receive?